GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 46,551 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,551 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $95.62, for a total transaction of $4,451,206.62. Following the completion of the sale, the chief executive officer now owns 48,314 shares in the company, valued at $4,619,784.68. This represents a 49.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total transaction of $96,416.32.
• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Trading Down 2.3 %

Shares of WGS traded down $2.14 during trading hours on Friday, reaching $92.20. 515,400 shares of the company traded hands, compared to its average volume of 640,718. The stock’s fifty day moving average price is $86.83 and its 200 day moving average price is $73.52. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of -47.04 and a beta of 1.91. GeneDx Holdings Corp. has a 12-month low of $8.53 and a 12-month high of $115.60.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Sell-side analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of WGS. MCF Advisors LLC grew its position in shares of GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after buying an additional 182 shares in the last quarter. Sterling Capital Management LLC grew its holdings in GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after acquiring an additional 316 shares in the last quarter. Global Retirement Partners LLC purchased a new position in GeneDx during the 4th quarter valued at about $28,000. Lazard Asset Management LLC bought a new stake in shares of GeneDx in the 4th quarter valued at about $35,000. Finally, Comerica Bank purchased a new stake in shares of GeneDx in the 4th quarter worth approximately $50,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on WGS. The Goldman Sachs Group boosted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen upped their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.